Market Newsdesk

BEIJING, April 14, 2026 (GLOBE NEWSWIRE) — Cheer Holding, Inc. (NASDAQ: CHR) (“Cheer Holding” or the “Company”), a leading provider of advanced mobile internet infrastructure and platform services, today announced the release of CHEERS Telepathy version 3.1.0, featuring new multimodal AI translation capabilities and a global AI assistant system.

The latest update underscores the Company’s commitment to making AI capabilities more accessible while enhancing collaborative creative workflows, further strengthening CHEERS Telepathy’s position in the AI agent space.

Multimodal AI Translation: Delivering Natural Cross-Language Interaction

With version 3.1.0, CHEERS Telepathy introduces a comprehensive AI translation suite, including real-time translation, face-to-face translation, text translation, and image translation.

Real-time and face-to-face translation serve as the flagship features. Built on an advanced end-to-end pipeline combining speech recognition, neural machine translation, and speech synthesis, the system enables near-natural cross-language dialogue. Low-latency voice streaming and semantic-level context modeling allow the platform to recognize and translate speech in real time, significantly lowering language barriers for international communication and other multilingual scenarios.

Expanded Multimodal Capabilities: Bridging Text and Visual Understanding

For text and image translation, CHEERS Telepathy integrates multimodal large model capabilities to achieve high-precision semantic understanding, translation generation, image content recognition, and joint image-text translation. By deeply fusing visual information with language models, the system not only recognizes text within images but also understands contextual meaning, delivering more natural and accurate translation results.

Global AI Assistant Upgrade: From Tool Invocation to Intelligent Collaboration

Beyond translation, CHEERS Telepathy 3.1.0 significantly enhances its AI assistant capabilities. Powered by large language models and designed with AI agent capabilities, the new assistant shifts the experience from single-point function calls to full-process intelligent collaboration. Users can complete an entire workflow—from expressing a need to generating results—without constantly switching between functional modules, enabling truly AI-native creation.

Core Capabilities of CHEERS Telepathy 3.1.0 Include:

· Real-Time & Face-to-Face Translation: Low-latency voice processing for conversational cross-language communication.
· Text & Image Translation: Multimodal understanding for accurate semantic and visual translation.
· Global AI Assistant: AI agent-driven support for seamless, end-to-end creative workflows.
· AI-Native Collaboration: Unified experience reducing friction across different tools and functions.

A Milestone in AI-Native Creative Systems

The release of CHEERS Telepathy 3.1.0 marks the product’s evolution from an AI tool to an AI collaboration system. As a new-generation, full-scenario AI agent creation engine, CHEERS Telepathy aims to make AI an extension of every user’s capabilities.

Looking ahead, Cheer Holding will continue to explore deep integration of large language models, multimodal technologies, and AI agent systems to further empower users in their creative and professional endeavors.

About Cheer Holding, Inc.

Cheer Holding is a leading provider of advanced mobile internet infrastructure and platform services. The Company operates a comprehensive digital ecosystem that integrates platforms, applications, technology, and industry, with a focus on AI-driven content creation, e-commerce, and metaverse development. For more information, please visit ir.gsmg.co.

Safe Harbor Statement

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to,” or other similar expressions. These forward-looking statements include, but are not limited to, statements regarding the success of our artificial intelligence initiatives, changes or other circumstances that could affect the Company’s ability to successfully develop and launch its product upgrades, AI initiatives, and technology infrastructure; issues relating to development and use of artificial intelligence; the possibility that the Company may not succeed in developing its new features due to, among other things, changes in the business environment and technological developments, competition, changes in regulation, or other economic and policy factors; and the possibility that the Company’s new features may be adversely affected by other economic, business, and/or competitive factors, or that the Company will be able to continue to have its Class A ordinary shares listed on The Nasdaq Capital Market. In addition, the Company is subject to a number of risks and uncertainties set forth in documents filed by the Company with the Securities and Exchange Commission from time to time, including the Company’s latest Annual Report on Form 20-F filed with the SEC on March 20, 2026. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Such information speaks only as of the date of this release.

For investor and media inquiries, please contact:

James Li
Email: [email protected]
Tel: +86 10 6778 2900 (CN)

AUSTIN, Texas, April 14, 2026 (GLOBE NEWSWIRE) — Commerce.com, Inc. (the “Company”) (Nasdaq: CMRC) (formerly BigCommerce Holdings, Inc.), a provider of an open, intelligent ecosystem of technology solutions that empower businesses to unlock data potential and deliver seamless, personalized experiences at scale, today announced that its Board of Directors (the “Board”) has adopted a limited duration stockholder rights plan (the “Rights Plan”). The Rights Plan is effective immediately and is scheduled to expire on April 12, 2027.

The Board adopted the Rights Plan in response to the unsolicited acquisition proposal made by Rezolve Ai PLC (NASDAQ: RZLV) on April 8, 2026 under which Rezolve Ai proposed to acquire all of the outstanding common shares of Commerce.com by exchanging one Rezolve Ai share for every two shares of Commerce.com, implying a 47% discount to the current Commerce.com share price, based on Rezolve Ai’s closing price of $2.88 on April 7, 2026. The Board, consistent with its fiduciary duties, carefully reviewed the unsolicited acquisition proposal and determined this proposal significantly undervalues the Company, is not attractive to Commerce.com stockholders, and does not warrant further engagement.

“The Board is committed to maximizing long-term value and acting in the best interests of all Commerce.com stockholders,” said Ellen Siminoff, Executive Chair of the Commerce Board of Directors. “The Rights Plan is intended to protect stockholder interests and ensure fair and equitable treatment, while providing the Board with the time and flexibility to thoroughly evaluate any transaction proposals in a deliberate and informed manner.”

Under the Rights Plan, one preferred stock purchase right will be distributed for each share of Commerce.com common stock held by stockholders of record on April 27, 2026. Under certain circumstances, each right will entitle stockholders to buy one one-thousandth of a share of newly created Series A Junior Participating Preferred Stock of the Company at an exercise price of $13.00. The Board will be entitled to redeem the rights at $0.01 per right at any time before a person or group has acquired 10% (20% in the case of a Passive Institutional Investor) or more of the outstanding common stock. The rights will expire on April 12, 2027, subject to the Company’s right to extend such date, unless earlier redeemed or exchanged by the Company or terminated.

Subject to limited exceptions, if a person or group acquires 10% (20% in the case of a Passive Institutional Investor) or more of the Company’s common stock (including shares deemed beneficially owned pursuant to derivative transactions or ownership of derivative securities), or announces a tender or exchange offer that, if consummated, would result in such ownership (each, an “acquiring person”), each right will entitle its holder to purchase, at the right’s then-current exercise price, a number of shares of common stock having a market value at that time of twice the right’s exercise price. Rights held by the acquiring person will become void and will not be exercisable. If the Company is acquired in a merger or other business combination transaction that has not been approved by the Board after the rights become exercisable, each right will entitle its holder to purchase, at the right’s then-current exercise price, a number of shares of the acquiring company’s common stock having a market value at that time of twice the right’s exercise price.

The dividend distribution to establish the new Rights Plan will be payable to stockholders of record on April 27, 2026. The rights distribution is not taxable to stockholders.

Further details about the Rights Plan will be contained in a Form 8-K to be filed by the Company with the Securities and Exchange Commission.

About Commerce

Commerce (Nasdaq: CMRC) empowers businesses to innovate, grow, and thrive by providing an open, AI-driven commerce ecosystem. As the parent company of BigCommerce, Feedonomics, and Makeswift, Commerce connects the tools and systems that power growth, enabling businesses to unlock the full potential of their data, deliver seamless and personalized experiences across every channel, and adapt swiftly to an ever-changing market. Trusted by leading businesses like Coldwater Creek, Cole Haan, Dell, Harvey Nichols, King Arthur Baking Co., Mizuno, Pacsun, Perry Ellis, Skechers, SportsShoes and Uplift Desk, Commerce delivers the storefront control, optimized data, and AI-ready tools businesses need to grow, serve diverse buyers, and operate with confidence in an increasingly intelligent, multi-surface world. For more information, visit commerce.com or follow us on X and LinkedIn.

Important Information for Investors and Stockholders

This press release does not constitute an offer to buy or solicitation of an offer to sell any securities. If a tender offer or exchange offer is commenced, the Company will file a solicitation/recommendation statement on Schedule 14D-9 with the SEC. Any solicitation/recommendation statement filed by the Company that is required to be mailed to stockholders will be mailed to stockholders. THE COMPANY’S INVESTORS AND STOCKHOLDERS ARE STRONGLY ENCOURAGED TO READ THE COMPANY’S SOLICITATION/RECOMMENDATION STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ALL OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and stockholders may obtain a copy of the solicitation/recommendation statement on Schedule 14D-9 (when available), any amendments or supplements thereto and other documents filed by the Company with the SEC at no charge at the SEC’s website at www.sec.gov. Copies will also be available at no charge by clicking the “SEC Filings” link in the “Financials” section of the Company’s website, https://investors.commerce.com, or by contacting [email protected] as soon as reasonably practicable after such materials are electronically filed with, or furnished to, the SEC.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terms such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “outlook,” “may,” “might,” “plan,” “project,” “will,” “would,” “should,” “could,” “can,” “predict,” “potential,” “strategy, “target,” “explore,” “continue,” or the negative of these terms, and similar expressions intended to identify forward-looking statements. However, not all forward-looking statements contain these identifying words. These statements may relate to our market size and growth strategy, our estimated and projected costs, margins, revenue, expenditures and customer and financial growth rates, our fiscal 2026 financial outlook, our plans and objectives for future operations, growth, initiatives or strategies. By their nature, these statements are subject to numerous uncertainties and risks, including factors beyond our control, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the forward-looking statements. These assumptions, uncertainties and risks include that, among others, the anticipated benefits and opportunities related to our 2025 realignment may not be realized or may take longer to realize than expected, our ability to pay the interest and principal on our indebtedness depends upon cash flows generated by our operating performance, our business would be harmed by any decline in new customers, renewals or upgrades, our limited operating history makes it difficult to evaluate our prospects and future results of operations, we operate in competitive markets, we may not be able to sustain our revenue growth rate in the future, our business would be harmed by any significant interruptions, delays or outages in services from our platform or certain social media platforms, and a cybersecurity-related attack, significant data breach or disruption of the information technology systems or networks could negatively affect our business. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption “Risk Factors” and elsewhere in our filings with the Securities and Exchange Commission (the “SEC”), including our Annual Report on Form 10-K for the year ended December 31, 2025 and the future quarterly and current reports that we file with the SEC. Forward-looking statements speak only as of the date the statements are made and are based on information available to Commerce.com, Inc. at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. Commerce.com, Inc. assumes no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, except as required by law.

Media Relations Contact

Brad Hem
[email protected]

Andrew Siegel / Sophie Throsby / Melissa Johnson
Joele Frank, Wilkinson Brimmer Katcher
(212) 355-4449

Investor Relations Contact

Tyler Duncan
[email protected]

CARLSBAD, Calif., April 14, 2026 (GLOBE NEWSWIRE) — Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its first quarter 2026 financial results after market close on Tuesday, May 5, 2026. Management will also host a conference call and concurrent webcast starting at 1:30 PM Pacific Time.

Conference Call Information

To participate in this event, dial in approximately 5 to 10 minutes before the start of the conference call.

Event Date: Tuesday, May 5, 2026
Time: 1:30 PM Pacific Time

Participant Registration: https://register-conf.media-server.com/register/BI34a01ff77922411f8b9d41f912e4159b

A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company’s website here.

About Carlsmed

Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond.

Investor Relations

[email protected]

Media

LeAnn Burton
Senior Director Brand Marketing
[email protected]

CARSON CITY, Nev., April 14, 2026 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced the acceptance of an abstract from its SUNRISE-PD study on lead candidate bezisterim (NE3107) in the treatment of patients with Parkinson’s Disease at the upcoming American Academy of Neurology Annual Meeting (AAN), to be held in Chicago, IL from April 18–22, 2026.

The abstract, titled A Study of NE3107 (Bezisterim) in Early Parkinson’s Disease (SUNRISE-PD): Baseline Demographics and Characteristic (J. Palumbo¹, C Ahlem¹, C.L. Reading¹, S. O’Quinn², J. Zhang³, M. Stacy⁴), summarizes the initial data on patients enrolled in the SUNRISE-PD study, and will be presented as a poster during the Movement Disorders Session on Parkinson’s Disease Emerging Therapeutics, on Monday, April 20, from 5:00 PM–6:00 PM CT.

Topline results from the SUNRISE-PD study are expected in mid‑2026.

The AAN is the leading voice in brain health. As the world’s largest association of neurologists and neuroscience professionals with 44,000+ members, the AAN offers access to continuing education, essential practice tools, research grants, networking and advocacy opportunities, and more.

Affiliations: ¹BioVie, Inc, ²Perissos, Inc., ³Princeton Pharmatech, ⁴Medical University of South Carolina

About Bezisterim

Bezisterim (NE3107) is an oral drug that crosses the blood-brain barrier and works to reduce inflammation and improve insulin sensitivity without suppressing the immune system and with a low risk of drug-drug interactions. By modulating key pathways involved in neuroinflammation (ERK, NFκB, TNF-α), bezisterim may have therapeutic potential in several disease indications, including Parkinson’s disease, Long COVID, and Alzheimer’s disease.

In Parkinson’s disease, BioVie has already completed a Phase 2 study that showed patients with moderate- to severe Parkinson’s taking bezisterim with levodopa had better motor control and fewer morning symptoms compared to those taking levodopa alone. Few drug-related side effects were observed. The current SUNRISE-PD just completed enrolling 60 patients to evaluate whether bezisterim alone can help improve motor and non-motor symptoms for Parkinson’s patients who have not been treated with carbidopa/levodopa. Topline results are expected in mid‑2026.

For Long COVID, the ADDRESS-LC trial is enrolling about 200 patient to evaluate if bezisterim can reduce brain fog, fatigue, and other lingering neurological symptoms associated with Long Covid, which are believed to be triggered by persistent circulation of spike protein fragments that trigger inflammation via NFκB activation (which bezisterim has been shown to modulate). Topline data is expected mid-2026.

In Alzheimer’s disease, BioVie has conducted both Phase 2 and Phase 3 trials. Early results suggest improvements in cognition and biomarkers, supporting further trials to evaluate its potential as a therapy for the six million Americans living with Alzheimer’s.

About BioVie Inc.

BioVie Inc. (NASDAQ: BIVI) is a clinical-stage biopharmaceutical company focused on developing therapies for neurological disorders and advanced liver disease. Its lead candidate, bezisterim (NE3107), targets neuroinflammation and insulin resistance, which are believed to be key drivers of Alzheimer’s and Parkinson’s disease. Bezisterim is also being studied for long COVID, where persistent inflammation is thought to underlie symptoms such as brain fog and fatigue.

In liver disease, BioVie is advancing BIV201, a continuous infusion of terlipressin treatment that has received FDA Orphan and Fast Track designations. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis, and the Company plans to study BIV201 in a Phase 3 trial for the reduction of further decompensation in patients with cirrhosis and ascites. For more information, visit www.bioviepharma.com.

For Investor Relations Inquiries:	For Media Inquiries:
Contact: Chuck Padala Managing Director, LifeSci Advisors, LLC [email protected]	Contact: Melyssa Weible Managing Partner, Elixir Health Public Relations  [email protected]

On track to complete 16-week, dose-finding Phase 1b study (n=240) in summer 2026

Phase 1b data will build upon Phase 1a findings that demonstrated weight loss of nearly
3% at 14 days in individuals with obesity

CRB-913 is a non-incretin daily oral small molecule with the potential to deliver a therapeutic option for weight loss and long-term weight management

NORWOOD, Mass., April 14, 2026 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on promising new therapies in oncology and obesity, today announced the last patient has been enrolled and completed the first clinical visit (Last Patient First Visit) in the Company’s CANYON-1 Phase 1b clinical trial of CRB-913 for the treatment of obesity. The CANYON-1 study is on track to be completed in the summer of 2026. CRB-913 is a once-daily highly peripherally restricted oral CB1 inverse agonist potentially offering an orthogonal approach to weight loss and long-term weight management.

The CANYON-1 Phase 1b clinical trial is a 16-week, double-blind, placebo-controlled, dose-ranging study in 240 obese, non-diabetic participants, and is being conducted at multiple clinical sites in the United States. The trial includes a placebo cohort and three CRB-913 cohorts of 20 mg, 40 mg, and 60 mg dosed orally once-daily (QD). A dose titration regimen is included in the design, with all CRB-913 participants commencing at 20 mg/day and then titrating up to either 40 mg/day or beyond that to 60 mg/day, depending on their respective cohorts. Participants are dosed for 3 months and are then monitored for an additional month post-dosing.

“Despite the remarkable success of GLP-1s and the incretin class, significant treatment gaps exist for millions of people struggling with obesity. In the real-world setting, over 40% of those who try incretin therapy turn out to be either intolerant or non-responsive to these drugs. These factors contribute to the high discontinuation rate of over 60% for this class. These statistics underscore the need for new, additional mechanisms to address obesity,” said Yuval Cohen, PhD, Chief Executive Officer of Corbus. “We look forward to our upcoming Phase 1b data readout that will help further inform CRB-913’s potential to deliver a novel, non-incretin drug and therapeutic option for weight loss and long-term weight management.”

About the CRB-913 Phase 1a Study Findings

Corbus completed a single ascending dose (SAD) and multiple ascending dose (MAD) Phase 1a study of CRB-913 in December 2025. The SAD portion of the trial enrolled 64 participants across 8 cohorts. The MAD portion enrolled 48 participants across 4 cohorts, including a dedicated obese cohort. The highest SAD dose tested was 600 mg/day, and the highest MAD dose tested was 150 mg/day. In the dedicated obese MAD cohort (150 mg/day), all CRB-913-treated participants (n=9), and none in the placebo group (n=3), experienced weight loss. The CRB-treated participants achieved a mean 2.9% placebo-adjusted weight loss by Day 14. Weight loss started early and deepened with time. CRB-913 was safe and well-tolerated across all cohorts and all doses studied, including demonstrating a very favorable GI profile with no reports of vomiting, constipation or nausea. Daily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative.

About Corbus

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focusing on promising new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate for the treatment of Nectin-4-expressing tumors, and CRB-913, an orally delivered highly peripherally restricted CB1 inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

INVESTOR CONTACTS:

Sean Moran
Chief Financial Officer
Corbus Pharmaceuticals
[email protected]

Dan Ferry
Managing Director
LifeSci Advisors, LLC
[email protected]

MEDIA CONTACT:

Liz Melone
Founder & Principal
Melone Communications, LLC
[email protected]

FORT WAYNE, Ind., April 14, 2026 (GLOBE NEWSWIRE) — Franklin Electric Co., Inc. (NASDAQ: FELE) will release its first quarter 2026 earnings at 8:00 am ET on Tuesday, April 28, 2026. A conference call to review earnings and other developments in the business will commence at 11:00 am ET. The first quarter 2026 earnings call will be available via a live webcast. The webcast will be available in a listen only mode by going to:

https://edge.media-server.com/mmc/p/h2get6o9

For those interested in participating in the question-and-answer portion of the call, please register for the call at the link below.

https://register-conf.media-server.com/register/BIcf2a85f3283f459faa88aeb69269ccab

All registrants will receive dial-in information and a PIN allowing them to access the live call. It is recommended that you join 10 minutes prior to the event start (although you may register and dial in at any time during the call).

A replay of the conference call will be available from Tuesday, April 28, 2026, through 11:00 am ET on Tuesday, May 5, 2026, by visiting the listen-only webcast link above.

About Franklin Electric


Franklin Electric is a global leader in the production and marketing of systems and components for the movement of water and energy. Recognized as a technical leader in its products and services, Franklin Electric serves customers worldwide in residential, commercial, agricultural, industrial, municipal and fueling applications. Franklin Electric is proud to be recognized in Newsweek’s lists of America’s Most Responsible Companies 2025, Most Trustworthy Companies 2025, and Greenest Companies 2025. 

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein, including those relating to market conditions or the Company’s financial results, costs, expenses or expense reductions, profit margins, inventory levels, foreign currency translation rates, liquidity expectations, business goals and sales growth, involve risks and uncertainties, including but not limited to, risks and uncertainties with respect to general economic and currency conditions, various conditions specific to the Company’s business and industry, weather conditions, new housing starts, market demand, competitive factors, changes in distribution channels, supply constraints, effect of price increases,  raw material costs, technology factors, integration of acquisitions, litigation, government and regulatory actions, the Company’s accounting policies, future trends, epidemics and pandemics, and other risks which are detailed in the Company’s Securities and Exchange Commission filings, included in Item 1A of Part I of the Company’s Annual Report on Form 10-K for the fiscal year ending December 31, 2025, Exhibit 99.1 attached thereto and in Item 1A of Part II of the Company’s Quarterly Reports on Form 10-Q. These risks and uncertainties may cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements made herein are based on information currently available, and the Company assumes no obligation to update any forward-looking statements.

CONTACT:	Jennifer Wolfenbarger / Dean Cantrell Franklin Electric Co., Inc. 260.824.2900

PHOENIX, April 14, 2026 (GLOBE NEWSWIRE) — Cavco Industries, Inc. (Nasdaq: CVCO) announced today that the Company has received two national design awards from the Manufactured Housing Institute (MHI) at the 2026 MHI Congress & Expo in Las Vegas, Nevada. 

As one of the nation’s leading providers of homes focused on factory-built and off-site construction, Cavco continues to expand access to high-quality housing through design, innovation and scale. The recognition highlights Cavco’s continued focus on design innovation, product quality and expanding access to modern, affordable housing.

MHI’s annual Excellence in Manufactured Housing Awards recognize companies across the manufactured and modular housing industry for product innovation, creative solutions and leadership. Each year, MHI invites submissions from manufacturers, vendors, retailers, communities and other strategic partners to compete across 18 categories, with more than 80 entries submitted in 2026. The awards highlight organizations that set the standard for serving customers and strengthening communities.

Cavco received recognition in the following categories: 

Manufactured Home Design – Single-Section: the Serenity Cabana, a single-section manufactured home featuring a modern single-slope roofline, stunning trapezoidal clerestory windows and soaring lofted ceilings. The striking contemporary design proves that efficient living space can make a bold architectural statement. The home was built by Cavco’s Millersburg, Oregon manufacturing facility.

Modular Home Design Award: the Luxus, a 3,000 sq. ft., 3-section modular home designed to deliver an open living concept in a larger footprint with elegant finishes and details at an affordable price point. The natural flow of the layout supports today’s lifestyles through open gathering zones and optional flex areas for working from home or extended family members. The home was built by Cavco’s Goshen, Indiana manufacturing facility.

“These awards recognize our continued focus on thoughtful design, build quality and innovation,” said Brian Cira, Cavco President, Manufactured Housing. “It reinforces the work our teams do every day to deliver homes that meet evolving customer expectations across both manufactured and modular construction.”

Housing affordability is at a critical point, and many buyers feel priced out of the home market. Cavco homes give buyers more affordable options without compromising quality. By building homes in controlled environments, Cavco is able to reduce waste, improve material use, shorten construction timelines and consistently deliver high-quality, high-value homes. Every efficiency gained in Cavco’s factories supports their mission to provide affordable homeownership for those who dream of owning homes.

For more information about Cavco Industries, visit cavcohomes.com.

About Cavco

Cavco Industries, Inc., headquartered in Phoenix, Arizona, designs and produces factory-built housing products primarily distributed through a network of independent and Company-owned retailers. We are one of the largest producers of manufactured and modular homes in the United States, based on reported wholesale shipments. We are also a leading producer of park model RVs, vacation cabins and factory-built commercial structures. Cavco’s finance subsidiary, CountryPlace Mortgage, is an approved Fannie Mae and Freddie Mac seller/servicer and a Ginnie Mae mortgage-backed securities issuer that offers conforming mortgages, non-conforming mortgages and home-only loans to purchasers of factory-built homes. Our insurance subsidiary, Standard Casualty, provides property and casualty insurance to owners of manufactured homes.

Multimedia Files:

Cavco Industries Inc. wins the 2026 MHI Excellence in Manufactured Housing Award in the Manufactured Home Design – Single-Section category for the Serenity Cabana.

Download:

Download original 2.5 MB (1600 x 900)

Download thumbnail 5 KB (100 x 56)

Download low-res 55 KB (500 x 281)

Cavco Industries Inc. wins the 2026 MHI Excellence in Manufactured Housing Award in the Modular Home Design category for the Luxus.

Download:

Download original 2.5 MB (1600 x 900)

Download thumbnail 5 KB (100 x 56)

Download low-res 55 KB (500 x 281)

For additional information, contact:


Colleen Rogers

SVP – Marketing & Communications
[email protected]
Phone: 972-763-5038
On the Internet:www.cavcohomes.com

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/ed1c4bea-9134-4a37-8855-129c35f19b57

https://www.globenewswire.com/NewsRoom/AttachmentNg/4ba3de53-a73f-4955-8fac-b1f6dec8155e

• Positive real-world head-to-head data on GraftAssure^TM assay to be presented at the 39^th European Immunogenetics and Histocompatibility Conference (EFI2026), April 21–24, 2026 in Edinburgh, Scotland
• Three posters to be presented at the 63^rd European Renal Association (ERA) Congress, June 3–6, 2026 in Glasgow, Scotland
• Favorable real-world evidence poster to be presented at the American Transplant Congress (ATC), June 20–24, 2026 in Boston
• Unaudited first quarter 2026 cash balance of $29.4 million is in line with year-end and Q4 2025 conference call guidance
• Company to host fireside chat and one-on-one meetings with investors at Needham Virtual Healthcare Conference on Wednesday, April 15^th

NASHVILLE, Tenn., April 14, 2026 (GLOBE NEWSWIRE) — Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today announced that its industry conference schedule this spring will highlight new independent clinical data supporting its GraftAssure^TM technology and support continued commercial and clinical engagement with the global transplant community.

The positive data presented on iMDx’s flagship GraftAssure technology will be presented by independent researchers, at leading institutions from the U.S., U.K. and the E.U., at three large international congresses in immunogenetics, nephrology, and transplantation. The release of this data furthers the partnership that iMDx has leveraged with the international transplant community, allowing the company’s partners to take control of their testing needs and deliver fast turnaround results.

“We are excited to help transplant centers get the tools they need to manage their patients,” iMDx CEO Josh Riggs said. “And we are thrilled that independent researchers are starting to publish their own data using our assay.”

At both EFI and ATC, beyond the respective GraftAssure data presentations, iMDx will have a strong exhibiting presence to drive additional participation in the company’s GALACTIC registry study (U.S. only, described below) and use of GraftAssureIQ, the research-use-only version of its assay. The company will also be coordinating with top transplant physicians on future applications of GraftAssure, beyond kidney transplant rejection testing.

For context, iMDx is seeking to deliver the industry-leading molecular diagnostic test kit for clinical use that expands and improves access to organ health testing for kidney transplant patients. The company expects that enabling localized testing will deliver new value in the roughly $2 billion addressable market for kitted transplant rejection testing.

As detailed in the company’s recent quarterly shareholder letter, iMDx submitted GraftAssureDx for regulatory review on March 25, 2026. GraftAssureDx represents, to iMDx’s knowledge, the first ever kitted dd-cfDNA assay to be submitted to the FDA for regulatory review. As such, the submission to the FDA is following the Class II de novo pathway, which the FDA uses for new, moderate-risk medical devices that do not fall into a pre-existing category.

Separately Tuesday, iMDx issued a reminder that it would be hosting a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. (Please see Webcast link below.) The company also reported a preliminary unaudited first quarter 2026 laboratory services revenue and a cash on hand update.

As a reminder, relative to the company’s strategic goal of selling diagnostic test kits for clinical use, iMDx considers itself to be essentially “pre-revenue.” The company recognized $32,000 in laboratory services revenue in the first quarter of 2026, which are contracted services performed at the request of select clients.

In addition, iMDx’s unaudited first quarter ending cash balance, including restricted cash, of $29.4 million reflects approximately $24.6 million in net proceeds from the company’s February registered direct financing, along with other cash inflows and outflows during the quarter. This is in line with the company’s projections given on its March 26, 2026 quarterly conference call.

Attendance at 25th Annual Needham Virtual Healthcare Conference

On April 15th, Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend the 25th Annual Needham Virtual Healthcare Conference.

Event: 25th Annual Needham Virtual Healthcare Conference
Presentation Date: April 15, 2026
Format: Virtual fireside chat and one-on-one meetings
Webcast: Click here

Investors wishing to book a meeting are encouraged to reach out to their Needham sales representative.

Forward-Looking Statements 

Any statements that are not historical fact (including, but not limited to, statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” “may,” and similar expressions) are forward-looking statements. These statements include those pertaining to, among other things,  upcoming presentations and attendance by iMDx at industry conferences, the company’s plans to deliver GraftAssureDx as an industry-leading molecular diagnostic kit for clinical use,
the FDA’s review of iMDx’s submission of GraftAssureDx,  the company’s GALACTIC registry study, iMDx’s preliminary financial results (including preliminary laboratory services revenue for the quarter ended March 31, 2026, and cash information as of March 31, 2026), and other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. 

The company’s preliminary unaudited first quarter 2026 revenue and cash amount at March 31, 2026, included in this press release are based on the management’s initial analysis of results of operations for the first quarter of 2026 and may be adjusted as a result of, among other things, completion of our review procedures. The company’s consolidated financial statements for the first quarter of 2026 are not yet available, remain subject to completion of our review procedures, financial closing procedures and potential final adjustments and have not been reviewed by the company’s independent registered public accounting firm. This financial information does not represent a comprehensive statement of the company’s financial results for the first quarter of 2026 and are not necessarily indicative of future results. There can be no assurance that actual results will not differ from the preliminary estimates in this press release. The company expects to file its full financial results for its first quarter 2026 in due course, along with the filing of its Quarterly Report on Form 10-Q with the Securities and Exchange Commission.

Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Insight Molecular Diagnostics’ third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with respect to licensed or acquired technology and products, the need to obtain third party reimbursement for patients’ use of any diagnostic tests Insight Molecular Diagnostics or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Insight Molecular Diagnostics, particularly those mentioned in the “Risk Factors” and other cautionary statements found in Insight Molecular Diagnostics’ Securities and Exchange Commission (SEC) filings, which are available from the SEC’s website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Insight Molecular Diagnostics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. 

iMDx Transplant Products and Product Candidates in Development

iMDx’s flagship transplant testing technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). The company’s scientists in Germany and the U.S. have played a critical role over the past decade in developing the science that helped establish dd-cfDNA as a trusted biomarker of transplant rejection. iMDx is commercializing this technology using a market-disruptive business strategy. Under the GraftAssure™ brand, iMDx’s transplant diagnostics include the following:

• GraftAssureCore – The company’s laboratory-developed test (LDT), currently reimbursed by CMS and performed at iMDx’s CLIA-certified laboratory in Franklin, Tennessee.
• GraftAssureIQ – A research-use-only (RUO) kit intended and labeled for non-clinical applications.
• GraftAssureDx – The in vitro diagnostic (IVD) kit currently in development for use in clinical decision-making.

This press release concerns references to certain products which are under clinical investigation, and which have not yet been cleared for marketing by the U.S. Food and Drug Administration. These products are currently limited by federal law to investigational use, and no representation is made as to the safety or effectiveness of these products for the purposes for which they are being investigated.

Registry Study

The GALACTIC registry study (GraftAssure Lowering Allograft rejeCTIon by Combination) is designed to drive clinical adoption and build a scientific case for iMDx’s unique combined score, which uses two independent measurements of dd-cfDNA. All participating registry centers will have an option to convert to in-house testing.

About Insight Molecular Diagnostics Inc.

Insight Molecular Diagnostics is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. Investors may visit https://investors.imdxinc.com/ for more information.

GraftAssureCore™, GraftAssureIQ™, GraftAssureDx™, GraftAssure™, are trademarks of Insight Molecular Diagnostics Inc.

Investor Contact:

Alexandra Grossman
LifeSci Advisors LLC
[email protected]

• Milestone builds on prior agreement for nuclear-grade graphite and supports SOLO™ FOAK (First-of-a-Kind) deployment targeted for 2027 and NOAK (Nth-of-a-Kind) commercialization in 2028
• Leveraging Mersen’s expertise in nuclear-grade materials, the companies successfully produced a graphite prototype (i.e. an engineering prototype) to support SOLO™ FOAK development
• The graphite engineering prototype has been successfully manufactured to required tolerances, validating reactor system integration and readiness for scalable, serialized production

NEW YORK and PARIS, April 14, 2026 (GLOBE NEWSWIRE) — Terra Innovatum Global N.V. (NASDAQ: NKLR), developer of the SOLO™ Micro-Modular Reactor, and Mersen (Euronext FR0000039620 – MRN), a global expert in electrical power and advanced materials, today announced the successful production of a graphite reactor core prototype marking an important step in manufacturing readiness for its FOAK reactor deployment. The milestone highlights the companies’ collaboration in advancing next-generation nuclear technologies. It demonstrates also Terra Innovatum’s progress in converting supply chain preparation into manufacturing execution as it advances toward FOAK deployment and NOAK commercialization.

“This advance marks an important step in our transition from supply chain readiness to manufacturing execution,” said Alessandro Petruzzi, Co-Founder and Chief Executive Officer of Terra Innovatum. “The successful production of the graphite reactor core prototype, achieved with Mersen, demonstrates our ability to secure and process the nuclear-grade materials essential to SOLO™ FOAK deployment. Just as importantly, it reinforces the industrial foundation needed to scale from first deployment to repeatable NOAK manufacturing.”

“The development of this graphite engineering prototype represents a meaningful technical milestone in the realization of the SOLO™ reactor core,” said Marco Cherubini, Co-Founder and Chief Technology Officer of Terra Innovatum. “These components are designed to host critical systems and core elements that influence thermal performance, and overall system reliability. This work also establishes the procedures and quality standards required for repeatable manufacturing and scalable deployment.”

Luc Themelin, Chief Executive Officer Mersen stated: “We are proud to contribute our materials expertise as a partner in advancing a new generation of advanced nuclear solutions, which will play an important role in delivering reliable and low-carbon energy. This collaboration reflects the growing role of advanced materials in enabling these technologies, as well as our ability to identify and support emerging growth drivers such as nuclear for the Group.”

This milestone builds on Terra Innovatum’s previously announced agreement with Mersen securing nuclear-grade graphite and procurement of critical materials required for SOLO™ FOAK deployment targeted for 2027 and NOAK commercialization beginning in 2028.

ABOUT MERSEN

Mersen is a global industrial group and a recognized expert in advanced materials. The world’s leading producer of isostatic graphite, Mersen develops customized, application-specific solutions for highly demanding sectors, including nuclear. The Group combines industrial scale with local execution – with more than 50 industrial sites in 30 countries, including Italy – enabling it to meet rigorous technical and regulatory standards for critical nuclear applications.

ABOUT TERRA INNOVATUM & SOLO

^TM

Terra Innovatum’s mission is to make nuclear power accessible. We deliver simple and safe micro-reactor solutions that are scalable, affordable and deployable anywhere 1 MWe at a time.

Terra Innovatum is a pioneering force in the energy sector, dedicated to delivering innovative and sustainable power solutions. Terra Innovatum plans to leverage cutting-edge nuclear technology through the SOLO™ Micro-Modular Reactor (SMR™) to provide efficient, safe, and environmentally conscious energy. With a mission to address global energy shortages, Terra Innovatum combines extensive expertise in nuclear industry design, manufacturing, and installation licensing to offer disruptive energy solutions. Committed to propelling technological advancements, Terra Innovatum and SOLO™ are dedicated to fostering prosperity and sustainability for humankind.

It is anticipated that SOLO™ will be available globally within the next three years. Conceptualized in 2018 and engineered over six years by experts in nuclear safety, licensing, innovation, and R&D, SOLO™ addresses pressing global energy demands with a market-ready solution. Built from readily available commercial off-the-shelf components, the proven licensing path for SOLO™ enables rapid deployment and minimizes supply chain risks, ensuring final cost predictability. Designed to adapt with evolving fuel options, SOLO™ supports both LEU+ and HALEU, offering a platform ready to transition to future fuel supplies.

SOLO™ will offer a wide range of versatile applications, providing CO2-free, behind-the-meter, and off-grid power solutions for data centers, mini-grids serving remote towns and villages, and large-scale industrial operations in hard-to-abate sectors like cement production, oil and gas, steel manufacturing, and mining. It also has the ability to supply heat for industrial applications and other specialized processes, including water treatment, desalination and co-generation. Thanks to its modular design, SOLO™ can easily scale to deliver up to 1GW or more of CO2-free power with a minimal footprint, making it an ideal solution for rapidly replacing fossil fuel-based thermal plants. Beyond electricity and heat generation, SOLO™ can also contribute to critical applications in the medical sector by producing radioisotopes essential for oncology research and cancer treatment.

To learn more, visit: https://investors.terrainnovatum.com/. Follow us on X: https://x.com/TerraInnovatum and LinkedIn: https://www.linkedin.com/company/terra-innovatum-solo/.

FORWARD LOOKING STATEMENTS

This press release includes “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, opinions and projections prepared by Terra Innovatum’s management. Forward-looking statements generally relate to future events or future financial or operating performance, including pro forma and estimated financial information, and other “forward-looking statements” (as such term is defined in the Private Securities Litigation Reform Act of 1995). The recipient can identify forward-looking statements because they typically contain words such as “outlook,” “believes,” “expects,” “ will,” “projected,” “continue,” “increase,” “may,” “should,” “could,” “seeks,” “predicts,” “intends,” “trends,” “plans,” “estimates,” “anticipates” or the negatives or variations of these words or other comparable words and/or similar expressions (but the absence of these words and/or similar expressions does not mean that a statement is not forward-looking). These forward-looking statements specifically include, but are not limited to, statements regarding estimates and forecasts of financial and performance metrics, projections of market opportunity and market share, expected timing for regulatory approvals and commercialization and the potential success of Terra Innovatum’s strategy and expectations. Forward-looking statements, opinions and projections are neither historical facts nor assurances of future performance. Instead, they are based only on current beliefs, expectations and assumptions regarding the future of Terra Innovatum’s business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Terra Innovatum’s control. These uncertainties and risks may be known or unknown. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: changes in domestic and foreign business, market, financial, political and legal conditions; failure to realize the anticipated benefits of the proposed business combination; risks relating to the uncertainty of the projected financial information with respect to Terra Innovatum; future global, regional or local economic and market conditions; the development, effects and enforcement of laws and regulations; Terra Innovatum’s ability to manage future growth; Terra Innovatum’s ability to develop new products and services, bring them to market in a timely manner, and make enhancements to its platform; the effects of competition on Terra Innovatum’s future business; and the outcome of any potential litigation, government and regulatory proceedings, investigations and inquiries and other risks and uncertainties described under the heading “Risk Factors” in documents Terra Innovatum files from time to time with the Securities and Exchange Commission. If any of these risks materialize or the Terra Innovatum’s assumptions prove incorrect, actual results could differ materially from the results implied by the forward-looking statements contained herein. In addition, forward-looking statements reflect Terra Innovatum’s expectations and views as of the date of this presentation. Terra Innovatum anticipates that subsequent events and developments will cause its assessments to change. However, while Terra Innovatum may elect to update these forward-looking statements in the future, each of them specifically disclaims any obligation to do so. Accordingly, you should not place undue reliance on the forward-looking statements, which speak only as of the date they are made.

CONTACTS – TERRA INNOVATUM

Giordano Morichi

Founding Partner, Chief Business Development Officer & Investor Relations
Terra Innovatum Global N.V.
E: [email protected]
W: www.terrainnovatum.com

Investor Relations
Simon Willcocks
Alliance Advisors IR
E: [email protected]

Media Relations
Fatema Bhabrawala
Alliance Advisors IR
E: [email protected]

CONTACTS – MERSEN

Investor Relations
Véronique Boca
E: [email protected]

Media Relations
Christophe Menger/Stephan Bürklin
Brunswick
E: [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4970a37a-0958-4130-9ca2-de5e608847fa